Articles

Nonmetastatic Non–Small-Cell Lung Cancer

Dr David Spigel reviews 5 practice-changing presentations from 2020 on the treatment of metastatic NSCLC using immunotherapy alone or in combination with chemotherapy or targeted agents. Read More ›

By Geoff Oxnard, MD

Small-Cell Lung Cancer and Mesothelioma

Dr Geoff Oxnard outlines promising results from the key studies from 2020 on the neoadjuvant or adjuvant treatment of resectable and/or nonmetastatic NSCLC, as well as the value of stereotactic body radiotherapy in place of surgery during the COVID-19 pandemic. Read More ›

By David Spigel, MD

Metastatic Non–Small-Cell Lung Cancer with Targetable Mutations

Dr David Spigel reviews the results of key studies from 2020 on novel approaches to first- or second-line treatment of SCLC and mesothelioma with both existing and emerging agents. Read More ›

By Geoff Oxnard, MD

Comparison of Healthcare Resource Utilization and Costs in Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Dr Geoff Oxnard provides an overview of novel approaches to metastatic NSCLC with targetable mutations, including established and newly discovered molecular targets. Read More ›

Incidence of Thrombotic Events with CDK4/6 Inhibitor Use in Real-World Practice Compared with Clinical Trial Settings

In this real-world setting study, similar healthcare costs and healthcare resource utilization among patients treated with ribociclib and palbociclib were observed. However, fewer inpatient days were experienced by patients treated with ribociclib when compared with abemaciclib. Read More ›

Assessment of Characteristics, Utilization Patterns, and Outcomes in the Real-World Setting of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with Abemaciclib

Thrombotic event incidence was higher in this real-world study than that which was reported in clinical trials, with arterial thrombosis accounting for more than one-third of events. Read More ›

Capecitabine or Endocrine Therapy as Maintenance Therapy for Hormone Receptor–Positive, HER2-Negative Breast Cancer

Results of this real-world study demonstrated that the impact of abemaciclib complements the pivotal clinical trial data. Read More ›

Real-World Data of Palbociclib and Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Primary analysis of a multicenter, randomized clinical trial suggests that endocrine therapy demonstrates benefits over capecitabine when used as a maintenance therapy after first-line combination chemotherapy in hormone receptor–positive, HER2-negative advanced metastatic breast cancer. Read More ›